Physician profile
Roy C Levitt
NPI 1588844013
$679.09
in general payments reported to CMS, 2019-2025
12 companies · $205 in 2025
The $205 reported for 2025 was more than what 81% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $17.41 · 2023: $119 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $323.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $253.54 | 2019-2025 | Eterna |
| Nevro Corp. | $146.70 | 2019 | |
| Averitas Pharma INC. | $93.51 | 2023 | Qutenza |
| Mml US, INC. | $49.75 | 2025 | Reactiv8 |
| Medtronic USA, INC. | $31.28 | 2019 | |
| Abbvie INC. | $25.48 | 2023 | |
| Tersera Therapeutics LLC | $19.00 | 2019 | |
| Allergan, INC. | $17.41 | 2020 | |
| Biodelivery Sciences International, INC. | $17.23 | 2019 | |
| Vertiflex, INC. | $14.28 | 2019 | |
| Stimwave Technologies Incorporated | $10.91 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Levitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.